Edition:
United Kingdom

PeptiDream Inc (4587.T)

4587.T on Tokyo Stock Exchange

4,685JPY
19 Dec 2018
Change (% chg)

¥205 (+4.58%)
Prev Close
¥4,480
Open
¥4,455
Day's High
¥4,700
Day's Low
¥4,415
Volume
897,200
Avg. Vol
837,240
52-wk High
¥5,780
52-wk Low
¥3,290

Latest Key Developments (Source: Significant Developments)

PeptiDream announces drug discovery and development agreement with Santen Pharmaceutical
Tuesday, 25 Sep 2018 

Sept 25(Reuters) - PeptiDream Inc <4587.T>:Says it has entered into a broad-based multi-target discovery and development agreement with Santen Pharmaceutical Co Ltd <<<4536.T>>>.  Full Article

PeptiDream says completion of technology transfer of Peptide Discovery Platform System to Shionogi
Thursday, 17 May 2018 

May 17 (Reuters) - PeptiDream Inc <4587.T>:Says co completed the transfer of co's proprietary Peptide Discovery Platform System (PDPS) technology to Shionogi & Co Ltd <<<4507.T>>>.Under the terms of the nonexclusive license agreement entered into by the co and Shionogi in June 2017, co will receive an undisclosed milestone payment and is eligible to receive additional technology access payments, in addition to payments based on achievement of certain predetermined development milestones for any constrained peptides and/or small molecules discovered from use of the PDPS technology.In addition, co is eligible to receive royalties on sales of certain products that arise from use of the PDPS technology .  Full Article

PeptiDream to invest 1.8 bln yen in peptide drugs unit
Friday, 30 Mar 2018 

March 30 (Reuters) - PeptiDream Inc <4587.T>:Says it will invest 1.8 billion yen in Osaka-based peptide drugs unit .Says it will hold 17.3 percent stake in Osaka-based unit after investment .  Full Article

Peptidream announces discovery collaboration agreement with Bayer
Monday, 20 Nov 2017 

Nov 19 (Reuters) - Peptidream Inc <4587.T>:Peptidream announces discovery collaboration agreement with bayer.‍Entered into a multi-target discovery collaboration with Germany-based Bayer AG​.Under terms , co would receive undisclosed upfront payment and research funding.Under terms, co is eligible to receive preclinical, clinical, commercialization milestone payments totaling up to $1.11 billion​.Also eligible to receive royalties on sales of any products that arise from collaboration​.  Full Article

PeptiDream announces discovery collaboration agreement with Bayer AG
Thursday, 16 Nov 2017 

Nov 16 (Reuters) - PeptiDream Inc <4587.T>:Says it announced today that it has entered into a multi-target discovery collaboration with Germany-based Bayer AG.Under the terms of the agreement, it would receive an undisclosed upfront payment and research funding and is eligible to receive preclinical, clinical, and commercialization milestone payments potentially totaling up to $1.11 billion (124.5 billion yen) .In addition, it is eligible to receive royalties on sales of any products that arise from the collaboration .  Full Article